[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas-neoplasms":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,75,106,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100563412","predictive-value-of-transcriptome-based-oncotreatoncotarget-and-organoid-testing-in-metastatic-pancreatic-cancer-100563412",false,"NCT06615830","Predictive Value of Transcriptome-based OncoTreat\u002FOncotarget and Organoid Testing in Metastatic Pancreatic Cancer.","HIPANC-002 - Observational Performance Study of Transcriptome-Based OncoTreat\u002FOncoTarget Testing With Patient-Derived Organoids in Metastatic Pancreatic Cancer","Inclusion criteria:\n\n* Informed Consent as documented by signature\n* Patients older than 18 years\n* Patients with metastatic pancreatic ductal adenocarcinoma\n* At least one lesion amenable for surgical excisional biopsy\n* ECOG Performance status 0-2\n* Radiologically measurable disease\n* Life expectancy \\> 3 months\n* Absolute leucocyte count \\>1.5 G\u002Fl, platelets \\>100 G\u002Fl\n* Serum creatinine \\\u003C1.5 times of the upper limit of normal or Clearance \\>50ml\u002Fmin (according to the CKD-EPI formula)\n\nExclusion criteria:\n\n* Known allergies or intolerance to one or more compounds present in one of the first line or second line regimens\n* Concomitant need for full anticoagulation that cannot be interrupted or bridged prior to tissue biopsy\n* ECOG PS \\>2\n* Heart failure (NYHA class III-IV)\n* Severe or uncontrolled concurrent illness\n* Active viral infection from HIV, HBV or HCV, even if under antiretroviral treatment\n* Myocardial infarction within the previous 6 months\n* Patients who are pregnant or breastfeeding","ALL","18 Years",{"count":19,"type":20},185,"ESTIMATED","OBSERVATIONAL","Pancreatic cancer is burdened by a survival of barely 10% at 5 years. About 80% of new cases do not qualify for surgery due to either locally-advanced or metastatic disease. In patients with good performance status (PS), palliative first-line treatments mainly consist of combination regimens, such as FOLFIRINOX, modified FOLFIRINOX or Gemcitabine-Abraxane. For subjects with a poor PS, instead, guidelines recommend single-agent infusions (e.g. Gemcitabine, Capecitabine or 5-FU alone). Nevertheless, upon disease progression therapeutic options are still scarce and with limited sustained efficacy.\n\nOverall survival in metastatic pancreatic cancer ranges between 9.1 and 13.5 months, while progression-free survival under either FOLFIRINOX or Gemcitabine-Abraxane spans between 5.5 and 6.4 months. This timespan reduces even further when standard second-line regimens must be initiated upon disease progression.\n\nNowadays, genomic and transcriptomic analysis are crucial tools in cancer research that enable the identification of genetic mutations and alterations that drive the development and progression of cancer. By studying the changes in the DNA and RNA sequences of cancer cells, researchers can gain insights into the underlying molecular mechanisms of cancer and identify potential therapeutic targets. Genomic analysis can identify specific mutations or alterations that are present in cancer cells, while transcriptomic analysis can reveal changes in gene expression that may be linked to disease progression or response to treatment. These analyses are an essential component for the development of precision medicine approaches, which aim to tailor cancer treatment to the individual genetic profile of each patient.\n\nPDOs can replicate in vitro the biological, genetic and molecular aspects of the primary tumour. Some of their advantages include their rapid growth compared to xenografts, the possibility to perform high-throughput drug screening, and their direct application to precision oncology by predicting best therapies. In this study they will be used as an in vitro comparator of the molecular tests to the clinical course of the patient.\n\nOverall, combining genomic and transcriptomic analysis with PDO technology in cancer research might lead to exponential capacity to provide oncologic patients with extremely tailored and effective cancer treatments in the future.\n\nFor HIPANC-002 these tests are being evaluated as non-interventional investigational IVD's. Test results are not to be used for protocol mandated therapy decisions.",[24,25,26,27],"Pancreas Neoplasms","Pancreatic Neoplasms","Pancreatic Cancer Metastatic","Pancreatic Adenocarcinoma Metastatic",[29,30,31,32,33,34,35,36],"Pancreatic cancer","Pancreatic adenocarcinoma","Metastatic pancreatic adenocarcinoma","Organoid","Organoid-driven chemotherapy","Darwin Oncotreat","Darwin Oncotarget","Personalized chemotherapy","NOT_YET_RECRUITING","2026-02-07",{"date":40,"type":41},"2026-02-11","ACTUAL",{"date":43,"type":20},"2026-06-01",{"date":45,"type":20},"2031-01",{"name":47,"class":48},"Prof. Dr. med. Dres. h.c. Jan Schmidt, MME","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":21,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100606261","proms-after-pancreatectomy-100606261","NCT07173257","PROMs After Pancreatectomy","Patient Reported Outcomes Measures in Patients Undergoing Pancreatic Resections","PERSPECTIVE","Inclusion Criteria:\n\n* Patients \\>18 years old who undergo pancreatic resection for any indication of any race, gender, or ethnicity who are fluent in English\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* Deemed not to have capacity to consent.",{"count":58,"type":20},250,"2 Years","The standard of care for a patient with resectable pancreatic is to perform pancreatic resection which, even in the modern era is associated with significant complications and impact on quality of life, often in the setting of poor survival even in the best scenario. Currently, there is a lack of data on patient quality of life after such procedures, how quality of life changes throughout the course of care, and whether patients who undergo these procedures are satisfied with their decision. This research is aimed to understand the impact of pancreatic surgery on patients' quality of life, how that impact changes over time, and patient satisfaction (or regret) with their decisions. This work will help improve the pre-operative conversation to help patients decide whether undergoing a pancreatic resection aligns with their post-operative goals of care.",[24,62,63],"Pancreatitis","Pancreatic Cyst","RECRUITING","2025-09-08",{"date":67,"type":41},"2025-09-15",{"date":69,"type":41},"2023-04-03",{"date":71,"type":20},"2026-12",{"name":73,"class":48},"University of Arizona",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100586359","antecolic-versus-retrocolic-gastrojejunostomy-during-whipples-procedure-100586359","NCT06914349","Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure","Antecolic Versus Retrocolic Gastrojejunostomy Following Pancreaticoduodenectomy: a Prospective Randomised Study","Inclusion Criteria:\n\n* Age over 18 years old\n* Elective pancreaticoduodenectomy\n* Signed consent form\n\nExclusion Criteria:\n\n* Age under 18 years old\n* Patients who are participants in other trials that may affect the results of this study\n* Patients who do not consent to participate in the study","80 Years",{"count":84,"type":20},76,"INTERVENTIONAL",[87],"NA","Aim: This randomized clinical study aims to compare occurrence of DGE in patients undergoing either antecolic or retrocolic gastrojejunostomy following pancreaticoduodenectomy.\n\nMethods: Participants of this study will be patients undergoing pylorus preserving pancreaticoduodenectomy at the Surgical Department of the University Hospital of Larissa. Patients will be randomized to undergo either an antecolic or a retrocolic gastrojejunostomy and the occurrence of DGE will then be compared between the two groups. Individuals younger than 18 or older than 75 years old, as well as patients who do not consent to participate in this trial, will be excluded.\n\nExpected results: Based on available literature, antecolic gastrojejunostomy may be related with a lower incidence of DGE, without a statistically significant difference between the two methods. We aim to show if one of the two methods of gastrointestinal reconstruction (antecolic versus retrocolic) affects DGE.",[90,24],"Pancreatic Cancer Resectable",[92,93,94,95],"Gastrojejunostomy","Whipple's","Antecolic","Retrocolic","2025-06-05",{"date":98,"type":41},"2025-06-06",{"date":100,"type":41},"2025-03-30",{"date":102,"type":20},"2029-03-31",{"name":104,"class":48},"University of Thessaly",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":85,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":105},"100591503","robotic-vs-open-pancreatoduodenectomy-100591503","NCT06981273","Robotic vs Open Pancreatoduodenectomy","SPAIN Trial Comparing Open vs Robotic Pancreatoduodenectomy","SPAIN PD","Inclusion Criteria:\n\n* Age 18 years or older.\n* Patients requiring planned pancreatoduodenectomy (robotic or open).\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who refuse the procedure.\n* Uncertainty about vascular involvement that could affect resectability.\n* Poor general health status (American Society of Anesthesiologists \\[ASA\\] classification IV).\n* Pancreatitis",{"count":115,"type":20},93,[87],"Pancreatic surgery, specifically pancreatoduodenectomy (PD), is a complex procedure often required for patients with pancreatic or other periampullary cancers. In recent years, minimally invasive techniques have become more popular, especially robotic-assisted surgery. However, there are limited studies comparing robotic surgery to traditional open surgery.\n\nThis is a national, multicenter study in Spain comparing the outcomes of robotic versus open pancreatoduodenectomy (PD). The main goal is to assess complications within 90 days after surgery. This study is important because it will provide evidence on which approach is safer and more effective for patients.\n\nThe study follows a \\*\\*prospective, randomized, and multicenter design\\*\\*, meaning patients are assigned to either robotic or open surgery randomly, and multiple hospitals are involved. The study will include all eligible patients undergoing planned PD surgery, either by robotic or open technique.\n\nTo be included in the study, patients must meet these conditions:\n\n* Be \\*\\*18 years or older\\*\\*.\n* Require \\*\\*planned PD surgery\\*\\*.\n* Sign an \\*\\*informed consent form\\*\\*.\n\nWho Cannot Participate?\n\nPatients will \\*\\*not\\*\\* be included if they:\n\n* \\*\\*Refuse the procedure\\*\\*.\n* Have \\*\\*uncertainty about vascular involvement\\*\\*.\n* Have a severe health condition classified as \\*\\*ASA IV\\*\\* (high-risk for surgery).\n\nThe main outcome measured will be the \\*\\*Comprehensive Complication Index (CCI), a standardized way to assess post-surgical complications. Additional factors being studied include:\n\n* \\*\\*Clinical outcomes\\*\\* during and after surgery.\n* \\*\\*Quality of life\\*\\* assessments.\n* \\*\\*Surgical costs\\*\\*.\n* \\*\\*Hospital stay duration\\*\\*.\n* \\*\\*Need to switch from robotic to open surgery\\*\\*.\n* \\*\\*Need for additional surgery (reoperations)\\*\\*.\n* \\*\\*Hospital readmissions\\*\\*.\n\nWhere Is the Study Being Conducted?\n\nThe study is being conducted in \\*\\*ten major hospitals across Spain\\*\\*:\n\n1. Hospital del Mar, Barcelona\n2. Hospital Balmis, Alicante\n3. Hospital Vall d'Hebron, Barcelona\n4. Arnau de Vilanova, Lleida\n5. Joan XXIII, Tarragona\n6. Hospital Sant Pau, Barcelona\n7. Germans Trias i Pujol, Barcelona\n8. Hospital Clínic, Barcelona\n9. HM Sanchinarro, Madrid\n10. Hospital Rio Hortega, Valladolid\n\nHow Long Will the Study Last? The study will take \\*\\*two years\\*\\* to complete, and patients will be followed for \\*\\*three years\\*\\* after surgery to track long-term outcomes.\n\nWhy Is This Study Important for Patients? For patients undergoing PD, this study will provide essential information about the risks and benefits of robotic versus open surgery. The findings will help doctors determine the best surgical approach, leading to improved safety, faster recovery, and better long-term health outcomes.\n\nIf you are a patient facing this type of surgery, participating in this study could contribute to valuable medical knowledge while ensuring that you receive a carefully monitored treatment plan.",[24],[120,121,122],"Robotic","pancreaticoduodenectony","Robotic surgery","2025-05-19",{"date":125,"type":41},"2025-05-20",{"date":127,"type":20},"2025-09-01",{"date":129,"type":20},"2027-09-01",{"name":131,"class":48},"Hospital del Mar",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":85,"phases":143,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":5},"100574281","phase-2-dovipa-a-study-evaluating-efficacy-and-safety-of-dostarlimab-and-vitamin-d3-with-mfolfirinox-in-pancreatic-cancer-100574281","NCT06757244","DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","DOVIPA, a Phase II Study Evaluating Efficacy and Safety of DOstarlimab and Oral VItamin D3 With Folinic Acid, 5FU, Irinotecan Plus Oxalipaltin (mFOLFIRINOX) in Non Pretreated Metastatic PAncreatic Cancer","DOVIPA","Inclusion criteria\n\n1. Histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas\n2. No prior treatment for stage IV pancreatic adenocarcinoma (prior adjuvant or neoadjuvant treatment is not allowed)\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1\n4. Male and female patients 18 - 75 years\n5. Measurable disease determined using guidelines of Response Evaluation Criteria In Solid Tumors (RECIST version 1.1)\n6. Accessible tumor tissue available for fresh biopsy\n7. Expected survival \\>3 months\n8. Men and women of child-bearing potential must agree to use adequate contraception.\n\n   A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:\n   * Is not a woman of childbearing potential (WOCBP), or\n   * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), from the screening visit to at least 6 months after the last dose of study treatment, and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of dostarlimab, and A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) within 72 hours before the first dose of study treatment.\n\n   Fertile men who are sexually active with a WOCBP must use a male condom plus spermicide during the trial and for 6 months after the last dose of study treatment administration. Male patients should also refrain from sperm donation throughout this period.\n9. Laboratory values ≤1 week prior to randomization must be Adequate hematologic values\n\n   * Platelet count ≥100,000 cells\u002Fmm3\n   * Absolute neutrophil count \\[ANC\\] ≥1,500 cells\u002Fmm3\n   * Hemoglobin ≥9 g\u002FdL or ≥90 g\u002FL) Adequate hepatic function\n   * Aspartate aminotransferase \\[AST\u002FSGOT\\] ≤2.5x Upper Normal Limit \\[UNL\\] (≤5x UNL if liver metastases present)\n   * Alanine aminotransferase \\[ALT\u002FSGPT\\] ≤ 2.5x Upper Normal Limit (≤5x UNL if liver metastases present)\n   * Bilirubin ≤1.5x UNL\n   * Serum albumin \\> 3.0 g\u002FdL Adequate renal function serum creatinine clearance CLcr ≥ 50 mL\u002Fmin) (Cocroft-Gault Formula should be used for CrCl calculation) For participants not taking warfarin: INR \\\u003C1.5 or PT \\\u003C1.5 x ULN and either PTT or aPTT \\\u003C1.5 x ULN. Participants taking warfarin may be included on a stable dose with a therapeutic INR \\\u003C3.5 Uracilemia \\\u003C 16 ng\u002Fml\n10. Patients with history of hepatitis C (HCV) infection are eligible if HCV viral load is undetectable at screening. HCV screening tests are not required unless there is a known history of HCV infection.\n11. No evidence of active infection and no serious infection within the past 30 days.\n12. Patient able to understand and willing to sign and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures\n13. Patient affiliated to a social security regimen\n\nNon-inclusion criteria\n\n1. Endocrine or acinar pancreatic carcinoma\n2. Participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal\u002Fgastric varices, or persistent jaundice.\n\n   Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.\n3. Major surgical procedure, significant traumatic injury within 28 days prior to study treatment start. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study\n4. Known cerebral metastases, central nervous system (CNS), or epidural tumor\n5. Prior anticancer treatment for adenocarcinoma of the pancreas including prior adjuvant or neoadjuvant treatment\n6. Known dose tivity reaction to any of the components of study treatments.\n7. Pregnancy (absence to be confirmed by β-hCG test) or breast-feeding period\n8. Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 months, or high risk of uncontrolled arrhythmia (for men: QTc ≥450 msec, for women: QTc ≥470 msec). Inclusion of patients with hypokalemia, hypomagnesemia and hypocalcemia (defined as results less than normal in Baseline testing) is not allowed.\n9. Previous malignancy in the last 5 years except curative treated basal cell carcinoma of the skin and\u002For in situ carcinoma of the cervix\n10. History or current evidence on physical examination of central nervous system disease or peripheral neuropathy ≥ grade 1 Common Toxicity Criteria for Adverse Events (CTCAE) v5.0.\n11. Any significant disease which, in the investigator's opinion, would exclude the patient from the study.\n12. Patient with a DPD deficiency or UGT1A1 homozygous 7\u002F7; the test should be done for all patients before 5-FU administration, according to ANSM communication regarding recommendation about high risk of no testing DPD in patient before 5-FU administration\n13. Has undergone prior allogeneic hematopoietic stem cell transplantation\n14. Has had an allogeneic tissue\u002Fsolid organ transplant\n15. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)\n16. Participant has received systemic steroid therapy (\\>10 mg daily prednisone or equivalent) within 7 days before the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy (adrenal or pituitary insufficiency) is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.\n17. Participant has received a live vaccine within 30 days of planned start of study therapy. COVID-19 vaccines that do not contain live viruses are allowed. Note: mRNA and adenoviral-based COVID-19 vaccines are considered non-live.\n18. History of or serology positive for HIV\n19. Patients who have documented presence of HBsAg \\[or HBcAb\\] at Screening or within 3 months prior to first dose of study intervention are excluded. HBV screening tests are not required unless there is a known history of HBV infection.\n20. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n21. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n22. Has an active infection requiring systemic therapy\n23. Allergy: Participant cannot have history of severe allergic and\u002For anaphylactic reactions to chimeric, human or humanized antibodies or fusion proteins, sensitivity to any of the study treatments or components thereof, or a history of drug or other allergy that contraindicates their participation.\n\n    In accordance with the updated SmPC of the products used in this trial, patient cannot be included in the following conditions:\n    * patient has a peripheral sensitive neuropathy with functional impairment prior to first course (contra-indication use with Oxaliplatin)\n    * concomitant use with St John's Wort - Chronic inflammatory bowel disease and\u002For bowel obstruction (contra-indication with Irinotecan)\n    * patient which has been treated with brivudine, sorivudine or their chemically related analogues, which are potent inhibitors of the enzyme dihydropyrimidine dehydrogenase (DPD), which degrades fluorouracil. Fluorouracil must not be taken within 4 weeks of treatment with brivudine, sorivudine or their chemically related analogues (contra-indication with fluorouracil)\n    * patient has diseases\u002Fconditions associated hypercalcaemia and \u002F or hypercalciuria. - Calcium nephrolithiasis, nephrocalcinosis, D- hypervitaminosis\n24. Being deprived of liberty or under guardianship\n25. Potential participants who are pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and\u002For unwilling to use highly effective contraception for up to 6 months after the last dose of study treatment are not eligible for the study.","75 Years",{"count":142,"type":20},35,[144],"PHASE2","The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas. The patients must have an Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) 0 or 1 and adequate organ functions.\n\nThe main objective of the study will be assessed by estimating Objective response rate (ORR) according to Response Evaluation Criteria version 1.1 (RECIST 1.1) in patients with pancreatic adenocarcinoma and measurable disease.\n\nThe Secondary objectives are :\n\n* To assess the safety and tolerability of mFOLFIRINOX + Dostarlimab + HD Vitamin D according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 by evaluating the Median Progression Free Survival (mPFS) in months, the Median Overall Survival (mOS) in months, the Median Duration of Response (mDOR) in months and Clinical benefit rate according to RECIST 1.1 (CBR)\n* To further evaluate the antitumor efficacy of mFOLFIRINOX + Dostarlimab + oral HD Vitamin D by evaluating the type, frequency, and severity of treatment-emergent adverse events (TEAEs); adverse events of special interest (AESIs); safety laboratory findings There are also exploratory objectives to better understand the pancreatic adenocarcinoma.\n\nParticipants will be cared for in the digestive oncology department. A selection review will be carried out to check compliance with the study eligibility criteria. Patients included in the study will be treated with 4 cycles of induction therapy. Each cycle lasts 6weeks and includes chemotherapy such as mFolfirinox D1,D15 and D29, combined with dostarlimab 500 mg every 3 weeks and daily oral vitamin D3.\n\nAt the end of the induction treatment period, maintenance treatment will be instituted with LV5FU chemotherapy combined with dostarlimab 1000 mg every 6 weeks and daily oral vitamine D3. Treatment will be maintained until progression or unacceptable toxicity.\n\nThroughout this period, patients will be monitored for their safety. Imaging examinations will also be carried out to monitor the progression of tumour disease.",[24],[30,148,149,150,151,152],"metastatic PAncreatic Cancer","dostarlimab","vitamin D3","mFolfirinox","LV5FU","2025-03-14",{"date":155,"type":41},"2025-03-18",{"date":157,"type":41},"2025-02-18",{"date":159,"type":20},"2028-02-18",{"name":161,"class":48},"Hopital Foch"]